Novartis reports that an experimental therapy for myotonic dystrophy type 1 (DM1) failed to achieve its main goal in a pivotal Phase 3 study, the company said on Tuesday. The HARBOR trial evaluated Novartis‘s investigational drug del-desiran and found no statistically significant improvement versus placebo on the trial’s prespecified measure of hand relaxation, known as video hand opening time (vHOT).
The HARBOR study enrolled adults with DM1, a progressive neuromuscular disorder marked by muscle stiffness and weakness. The trial’s primary endpoint centered on functional hand opening after contraction, a clinically relevant assessment for patients whose daily activities are compromised by myotonia. Secondary and exploratory outcomes have not been publicly detailed; the company indicated it will analyze the full data set to understand subgroup responses and safety findings.
This setback arrives days after the company disclosed a separate late-stage disappointment in a cardiovascular program, and it follows a recent regulatory success in multiple sclerosis that briefly brightened the outlook for the drugmaker. Together, the results are likely to intensify scrutiny of Novartis‘s broader development pipeline and its recent acquisition strategy as the firm confronts a looming patent cliff that could affect revenue in coming years. The mixed clinical readouts underscore the inherent uncertainty of translating early- phase promise into large-scale therapeutic benefit.
Company officials said they will review the HARBOR data and discuss next steps with investigators and regulators. For patients, clinicians and investors, the immediate consequence is a recalibration of expectations for del-desiran and an emphasis on alternative approaches for this rare condition. The result also highlights the challenges facing research into myotonic dystrophy and the broader field of rare diseases, where clinical trial design and meaningful functional endpoints remain central to assessing benefit. Stakeholders will be watching subsequent data releases and regulatory communications closely as the company outlines its path forward in the coming weeks and months, including any implications for ongoing or planned clinical trials.
